GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » EV-to-EBITDA

Sumitomo Pharma Co (Sumitomo Pharma Co) EV-to-EBITDA

: -4.85 (As of Today)
View and export this data going back to 2009. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sumitomo Pharma Co's enterprise value is $3,405 Mil. Sumitomo Pharma Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-702 Mil. Therefore, Sumitomo Pharma Co's EV-to-EBITDA for today is -4.85.

The historical rank and industry rank for Sumitomo Pharma Co's EV-to-EBITDA or its related term are showing as below:

DNPUF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.8   Med: 9.67   Max: 40.9
Current: -4.85

During the past 13 years, the highest EV-to-EBITDA of Sumitomo Pharma Co was 40.90. The lowest was -9.80. And the median was 9.67.

DNPUF's EV-to-EBITDA is ranked worse than
100% of 706 companies
in the Drug Manufacturers industry
Industry Median: 13.805 vs DNPUF: -4.85

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Sumitomo Pharma Co's stock price is $2.595. Sumitomo Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.113. Therefore, Sumitomo Pharma Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Sumitomo Pharma Co EV-to-EBITDA Historical Data

The historical data trend for Sumitomo Pharma Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.83 7.95 8.57 4.63 -140.91

Sumitomo Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.47 -140.91 -9.63 -9.53 -5.66

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co EV-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's EV-to-EBITDA falls into.



Sumitomo Pharma Co EV-to-EBITDA Calculation

Sumitomo Pharma Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=3405.092/-701.814
=-4.85

Sumitomo Pharma Co's current Enterprise Value is $3,405 Mil.
Sumitomo Pharma Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-702 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sumitomo Pharma Co  (OTCPK:DNPUF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sumitomo Pharma Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.595/-3.113
=At Loss

Sumitomo Pharma Co's share price for today is $2.595.
Sumitomo Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.113.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Sumitomo Pharma Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Traded in Other Exchanges
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.